

27 Sep 2024 | Analysis

Pink Sheet Podcast: Pfizer Pulls Sickle Cell Drug, ODAC Calls Back Approved Products, New AAM CEO

by **Pink Sheet Team**

Pink Sheet reporters and editors discuss Pfizer's abrupt decision to withdraw Oxbryta, the US FDA's Oncologic Drugs Advisory Committee bringing sponsors of approved products back to discuss labeling changes while competitors are pending, and the new CEO of a generic industry trade association.

Pink Sheet Executive Editor Derrick Gingery, Senior Writer Sarah Karlin-Smith, Reporter Alaric DeArment, and Interim Editor-in-Chief Nielsen Hobbs discuss the issues that lead [Pfizer Inc.](#) to pull the sickle cell disease treatment Oxbryta (voxelitor) from global markets (:32), the impact of the US Food and Drug Administration's Oncologic Drugs Advisory Committee meeting about labeling changes for approved drugs along with pending competitors (10:46), as well as the decision by the Association for Accessible Medicines to name John Murphy, a former brand trade association executive, as its new president and CEO (27:34).

[Click here to explore this interactive content online](#) ✨

More On These Topics From The Pink Sheet

- [Pfizer Withdraws Oxbryta, But Overall Market Impact May Be Limited](#)
- [EMA Discusses Fatal Events That Prompted Pfizer To Pull Oxbryta From Global Markets](#)
- [New US FDA Adcomm Trend: Approved Cancer Meds Get Another Look When Competitors Coming](#)

PINK SHEET

CITELINE REGULATORY

- [*All Comers No More? US FDA AdComm Supports PD-L1 Threshold In Esophageal, Gastric Cancer*](#)
- [*Pazdur Calls For 'Kumbaya' To Standardize ImmunoOncology Biomarkers*](#)
- [*New AAM CEO Looking To 'Force Multiply' For US Generics Industry*](#)

This and other podcasts are available on the *Pink Sheet* [podcast page](#), as well as the *Citeline* channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.